Your browser doesn't support javascript.
loading
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue, D; Kitaura, J; Matsui, H; Hou, H-A; Chou, W-C; Nagamachi, A; Kawabata, K C; Togami, K; Nagase, R; Horikawa, S; Saika, M; Micol, J-B; Hayashi, Y; Harada, Y; Harada, H; Inaba, T; Tien, H-F; Abdel-Wahab, O; Kitamura, T.
Afiliación
  • Inoue D; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Kitaura J; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Matsui H; Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Hou HA; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Chou WC; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Nagamachi A; Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Kawabata KC; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Togami K; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Nagase R; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Horikawa S; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Saika M; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Micol JB; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hayashi Y; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Harada Y; Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
  • Harada H; Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
  • Inaba T; Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Tien HF; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Abdel-Wahab O; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kitamura T; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Leukemia ; 29(4): 847-57, 2015 Apr.
Article en En | MEDLINE | ID: mdl-25306901
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Represoras / Síndromes Mielodisplásicos / Proteínas Nucleares / Leucemia Mieloide Aguda / Proteínas Portadoras / Regulación Leucémica de la Expresión Génica / Transformación Celular Neoplásica Tipo de estudio: Prognostic_studies Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Represoras / Síndromes Mielodisplásicos / Proteínas Nucleares / Leucemia Mieloide Aguda / Proteínas Portadoras / Regulación Leucémica de la Expresión Génica / Transformación Celular Neoplásica Tipo de estudio: Prognostic_studies Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido